Impact of 18 F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer
Journal of Clinical Oncology · 10.08.2023 · 41 (23) · 3909-3916
DOI: 10.1200/jco.23.00249 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2023. Verfasst von Ian S Dayes und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, McMaster University, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Breast Neoplasms. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Patients with locally advanced breast cancer (LABC) typically undergo staging tests at presentation. If staging does not detect metastases, treatment consists of curative intent combined modality therapy (neoadjuvant chemotherapy, surgery, and regional radiation). Positron emission tomography-computed tomography (PET-CT) may detect more asymptomatic distant metastases, but the evidence is based on uncontrolled studies. METHODS For inclusion, patients had histological evidence of invasive ductal carcinoma of the breast and TNM stage III or IIb (T3N0, but not T2N1). Consenting patients from six regional cancer centers in Ontario were randomly assigned to 18 F-labeled fluorodeoxyglucose PET-CT or conventional staging (bone scan, CT of the chest/abdomen and pelvis). The primary end point was upstaging to stage IV. A key secondary outcome was receiving curative intent combined modality therapy (ClinicalTrials.gov identifier: NCT02751710 ). RESULTS Between December 2016 and April 2022, 184 patients were randomly assigned to whole-body PET-CT and 185 patients to conventional staging. Forty-three (23%) PET-CT patients were upstaged to stage IV compared with 21 (11%) conventional staged patients (absolute difference, 12.3% [95% CI, 3.9 to 19.9]; P = .002). Consequently, treatment was changed in 35 (81.3%) of 43 upstaged PET-CT patients and 20 (95.2%) of the 21 upstaged conventional patients. Subsequently, 149 (81%) patients in the PET-CT group received combined modality treatment versus 165 (89.2%) patients in the conventional staging group (absolute difference, 8.2% [95% CI, 0.1 to 15.4]; P = .03). CONCLUSION In patients with LABC, PET-CT detected more distant metastases than conventional staging, and fewer PET-CT patients received combined modality therapy. Our randomized trial demonstrates the utility of the PET-CT staging strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, McMaster University, Hamilton, ON, Canada.
- Juravinski Cancer Centre-Hamilton Health Sciences, Hamilton, ON, Canada.
- Ontario Clinical Oncology Group, Hamilton, ON, Canada.
- Escarpment Cancer Research Institute, Hamilton, ON, Canada.
- Joint Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.
- University Health Network Princess Margaret Cancer Centre, Toronto, ON, Canada.
ORCID-Profile: Ian S Dayes, Ur Metser, Ralph George, Tulin D Cil, Mark N Levine
Zitieren
APA
Dayes, I. S., Metser, U., Hodgson, N., Parpia, S., Eisen, A. F., George, R., Blanchette, P., Cil, T. D., Arnaout, A., Chan, A., & Levine, M. N. (2023). Impact of 18 F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer. Journal of Clinical Oncology, 41(23), 3909-3916. https://doi.org/10.1200/jco.23.00249
Vancouver
Dayes IS, Metser U, Hodgson N, Parpia S, Eisen AF, George R, et al. Impact of 18 F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer. Journal of Clinical Oncology. 2023;41(23):3909-3916. doi:10.1200/jco.23.00249
BibTeX
@article{Dayes2023,
author = {Dayes, Ian S and Metser, Ur and Hodgson, Nicole and Parpia, Sameer and Eisen, Andrea F and George, Ralph and Blanchette, Phillip and Cil, Tulin D and Arnaout, Angel and Chan, Adrien and Levine, Mark N},
title = {Impact of 18 F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {23},
pages = {3909--3916},
doi = {10.1200/jco.23.00249}
}
EUVIMED